Sugi Predict

Sugi Predict / Compounds / SCHEMBL9980482

SCHEMBL9980482

SCHEMBL9980482

O=c1ccc2ncc(I)cc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK2 P49137 1/20 0.42
▸ RPS6KA3 P51812 1/20 0.42
▸ CSNK2A1 P68400 1/20 0.42
▸ PLK3 Q9H4B4 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ SMYD3 Q9H7B4 1/20 0.38
▸ PDE3B Q13370 4/20 0.38
▸ PDE3A Q14432 4/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ HCAR1 Q9BXC0 6/20 0.36
▸ PARP1 P09874 1/20 0.35
▸ CA12 O43570 2/20 0.34
▸ CA9 Q16790 2/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA3 P07451 1/20 0.34
▸ CA4 P22748 1/20 0.34
▸ CA6 P23280 1/20 0.34
▸ CA5A P35218 1/20 0.34
▸ CA7 P43166 1/20 0.34
▸ CA13 Q8N1Q1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18211315 0.85 MAPKAPK2 (0.50) MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1
SCHEMBL4137137 0.79 F11 (0.47) MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1
SCHEMBL31093789 0.79 F11 (0.47) MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1
SCHEMBL4135331 0.78 CA12 (0.46) MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1
SCHEMBL4135759 0.78 DYRK1A (0.49) MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1
SCHEMBL1378724 0.78 MAPKAPK2 (0.42) MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1
SCHEMBL30010831 0.74 PDE3B (0.44) MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1
SCHEMBL28869879 0.74 PDE3B (0.44) MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1
SCHEMBL28869893 0.74 MAPKAPK2 (0.39) MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1
SCHEMBL1374700 0.74 MMP12 (0.47) ALDH1A1PDE3BPDE3AHCAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228490-A1 HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2024-07-11 — — US disclosed
WO-2023134647-A1 PIPERAZINO RING-CONTAINING DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 优领医药科技(香港)有限公司 2023-07-20 — — WO disclosed
US-9682141-B2 Combination of kinase inhibitors and uses thereof INTELLIKINE LLC (US) 2017-06-20 — — US disclosed
US-9682141-B2 Combination of kinase inhibitors and uses thereof INTELLIKINE LLC (US) 2017-06-20 — — US disclosed
US-20160235758-A1 COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF INTELLIKINE LLC 2016-08-18 — — US disclosed
US-20160235758-A1 COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF INTELLIKINE LLC 2016-08-18 — — US disclosed
EP-2575462-B1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE LLC (US) 2016-06-22 — — EP disclosed
EP-2575462-B1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE LLC (US) 2016-06-22 — — EP disclosed
US-9359352-B2 Substituted benzimidazoles as PI3 kinase inhibitors INTELLIKINE LLC (US) 2016-06-07 — — US disclosed
US-9359352-B2 Substituted benzimidazoles as PI3 kinase inhibitors INTELLIKINE LLC (US) 2016-06-07 — — US disclosed
US-20130261102-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2013-10-03 — — US disclosed
WO-2013078441-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE, LLC (US) 2013-05-30 — — WO disclosed
WO-2013078441-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE, LLC (US) 2013-05-30 — — WO disclosed
WO-2013071264-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF INTELLIKINE, LLC (US) 2013-05-16 — — WO disclosed
EP-2575462-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Intellikine, LLC (US) 2013-04-10 — — EP disclosed
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF INTELLIKINE LLC (US) 2012-11-22 — — US disclosed
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF INTELLIKINE LLC (US) 2012-11-22 — — US disclosed
WO-2012148540-A1 COMBINATION OF KANASE INHIBITORS AND USES THREOF INTELLIKINE, LLC (US) 2012-11-01 — — WO disclosed
WO-2011149937-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE, INC. (US) 2011-12-01 — — WO disclosed
WO-2011149937-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INTELLIKINE, INC. (US) 2011-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228490-A1 HETEROCYCLIC DERIVATIVE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF WEE1, CYP51A1, WEE2 MAPKAPK2 1082/4885RPS6KA3 3067/4885CSNK2A1 1599/4885
US-20160235758-A1 COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF MTOR, RPTOR, RICTOR MAPKAPK2 278/4885RPS6KA3 17/4885CSNK2A1 452/4885
US-20130261102-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB MAPKAPK2 132/4885RPS6KA3 161/4885CSNK2A1 671/4885
US-20120294930-A1 COMBINATION OF KINASE INHIBITORS AND USES THEREOF MTOR, AKT2, MTMR1 MAPKAPK2 193/4885RPS6KA3 19/4885CSNK2A1 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.